ReviewCureus2024
Unveiling the Role of Biomarkers in Cardiovascular Risk Assessment and Prognosis.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Methods to assess atherosclerotic cardiovascular risk in chronic respiratory diseases: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Integrating Conventional and Emerging Approaches in Cardiovascular Risk Assessment and Management.Public health challenges · 2026Review
- Beyond traditional risk scores: The emerging role of biomarkers in cardiovascular risk stratification.American journal of preventive cardiology · 2026Article
- Pre-procedural IL-18, hs-CRP, and VEGF as predictors of adverse outcomes in acute myocardial infarction patients undergoing percutaneous coronary intervention.Frontiers in medicine · 2026Article
- High-Sensitivity Troponins and Homocysteine: Combined Biomarkers for Better Prediction of Cardiovascular Events.International journal of molecular sciences · 2025Review
- Novel cardiac biomarkers and multiple-marker approach in the early detection, prognosis, and risk stratification of cardiac diseases.World journal of cardiology · 2025Review
- Current and future role of biomarkers in the monitoring and prognosis of coronary artery disease.Future cardiology · 2025Article
- Association and predictability of major perioperative cardiovascular adverse events and elevated neutrophil percentage-to-albumin ratio in patients with stable coronary artery disease undergoing non-cardiac surgery.Frontiers in cardiovascular medicine · 2025Article
- Frontiers in plasma proteome profiling platforms: innovations and applications.Clinical proteomics · 2024Article
- Frontiers in Plasma Proteome Profiling Platforms: Innovations and Applications.Research square · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) remain a leading cause of global morbidity and mortality, necessitating innovative approaches for accurate risk assessment and prognosis. This review explores the evolving role of biomarkers in advancing cardiovascular risk evaluation and prognostication. Utilizing cardiac biomarkers that represent diverse pathophysiological pathways has the potential to enhance risk stratification for CVD. We delve into the intricate molecular signatures indicative of cardiovascular health, focusing on established biomarkers such as troponins, natriuretic peptides, and lipid profiles while also examining emerging candidates like microRNAs and inflammatory markers. This review provides a holistic perspective on the current landscape of cardiovascular biomarkers, offering insights into their applications in risk assessment and prognosis. In evaluating the risk and prognosis of heart failure (HF), the measurement of natriuretic peptides (B-type natriuretic peptide [BNP] or N-terminal pro-B-type natriuretic peptide [NT-proBNP]) or markers of myocardial injury (cardiac troponin I [TnI] or T [TnT]) has demonstrated utility. By elucidating the synergistic interplay between traditional markers and cutting-edge technologies, this work aims to guide future research endeavors and clinical practices, ultimately contributing to more effective strategies for risk assessment and prognosis of cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.